Published in Acta Pharmacol Sin on January 30, 2012
Mechanisms of altered Ca²⁺ handling in heart failure. Circ Res (2013) 1.37
Altered sarcoplasmic reticulum calcium cycling--targets for heart failure therapy. Nat Rev Cardiol (2012) 1.15
Targeting cardiac β-adrenergic signaling via GRK2 inhibition for heart failure therapy. Front Physiol (2013) 1.02
PKA catalytic subunit compartmentation regulates contractile and hypertrophic responses to β-adrenergic signaling. J Mol Cell Cardiol (2013) 0.87
Maternal diet-induced obesity programs cardiovascular dysfunction in adult male mouse offspring independent of current body weight. Endocrinology (2014) 0.86
Biased β2 -adrenoceptor signalling in heart failure: pathophysiology and drug discovery. Br J Pharmacol (2014) 0.82
Adrenergic receptors and metabolism: role in development of cardiovascular disease. Front Physiol (2013) 0.82
Administration of a selective β2 adrenergic receptor antagonist exacerbates neuropathology and cognitive deficits in a mouse model of Alzheimer's disease. Neurobiol Aging (2014) 0.82
Structure-bias relationships for fenoterol stereoisomers in six molecular and cellular assays at the β2-adrenoceptor. Naunyn Schmiedebergs Arch Pharmacol (2014) 0.80
Role of cyclic AMP sensor Epac1 in masseter muscle hypertrophy and myosin heavy chain transition induced by β2-adrenoceptor stimulation. J Physiol (2014) 0.79
Molecular interactions between fenoterol stereoisomers and derivatives and the β₂-adrenergic receptor binding site studied by docking and molecular dynamics simulations. J Mol Model (2013) 0.79
Inflammation and cardiac dysfunction during sepsis, muscular dystrophy, and myocarditis. Burns Trauma (2013) 0.78
A new era for GPCR research: structures, biology and drug discovery. Acta Pharmacol Sin (2012) 0.78
Sex differences in β-adrenergic responsiveness of action potentials and intracellular calcium handling in isolated rabbit hearts. PLoS One (2014) 0.78
β2 adrenergic receptor activation governs cardiac repolarization and arrhythmogenesis in a guinea pig model of heart failure. Sci Rep (2015) 0.78
Cypher/ZASP is a novel A-kinase anchoring protein. J Biol Chem (2013) 0.77
Advances in receptor conformation research: the quest for functionally selective conformations focusing on the β2 -adrenoceptor. Br J Pharmacol (2015) 0.76
Functional cross-talk between the α1- and β1-adrenergic receptors modulates the rapidly activating delayed rectifier potassium current in guinea pig ventricular myocytes. Int J Mol Sci (2014) 0.75
Three basic residues of intracellular loop 3 of the beta-1 adrenergic receptor are required for golgin-160-dependent trafficking. Int J Mol Sci (2014) 0.75
PDE2 activity differs in right and left rat ventricular myocardium and differentially regulates β2 adrenoceptor-mediated effects. Exp Biol Med (Maywood) (2014) 0.75
G-protein Coupled Receptor Signaling in Pluripotent Stem Cell-derived Cardiovascular Cells: Implications for Disease Modeling. Front Cell Dev Biol (2015) 0.75
β-arrestin-biased signaling through the β2-adrenergic receptor promotes cardiomyocyte contraction. Proc Natl Acad Sci U S A (2016) 0.75
Skeletal Muscle-specific G Protein-coupled Receptor Kinase 2 Ablation Alters Isolated Skeletal Muscle Mechanics and Enhances Clenbuterol-stimulated Hypertrophy. J Biol Chem (2016) 0.75
Activation of β-adrenergic receptor promotes cellular proliferation in human glioblastoma. Oncol Lett (2017) 0.75
MECHANISMS UNDERLYING ACTION OF XINMAILONG INJECTION, A TRADITIONAL CHINESE MEDICINE IN CARDIAC FUNCTION IMPROVEMENT. Afr J Tradit Complement Altern Med (2017) 0.75
Mdm2 regulates cardiac contractility by inhibiting GRK2-mediated desensitization of β-adrenergic receptor signaling. JCI Insight (2017) 0.75
How many drug targets are there? Nat Rev Drug Discov (2006) 14.22
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet (1999) 11.26
Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF) Lancet (1999) 10.07
Executive summary: heart disease and stroke statistics--2010 update: a report from the American Heart Association. Circulation (2010) 9.18
Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med (2001) 7.05
Functional selectivity and classical concepts of quantitative pharmacology. J Pharmacol Exp Ther (2006) 7.03
Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts. N Engl J Med (1982) 6.79
Switching of the coupling of the beta2-adrenergic receptor to different G proteins by protein kinase A. Nature (1997) 5.31
Altered expression of beta-adrenergic receptor kinase and beta 1-adrenergic receptors in the failing human heart. Circulation (1993) 4.52
G protein-coupled receptors. III. New roles for receptor kinases and beta-arrestins in receptor signaling and desensitization. J Biol Chem (1998) 4.37
Beta-arrestin-biased ligands at seven-transmembrane receptors. Trends Pharmacol Sci (2007) 4.35
Cardiac function in mice overexpressing the beta-adrenergic receptor kinase or a beta ARK inhibitor. Science (1995) 4.18
A GRK5 polymorphism that inhibits beta-adrenergic receptor signaling is protective in heart failure. Nat Med (2008) 3.98
Meta-analysis: angiotensin-receptor blockers in chronic heart failure and high-risk acute myocardial infarction. Ann Intern Med (2004) 3.96
A unique mechanism of beta-blocker action: carvedilol stimulates beta-arrestin signaling. Proc Natl Acad Sci U S A (2007) 3.82
The conserved phosphoinositide 3-kinase pathway determines heart size in mice. EMBO J (2000) 3.64
Role of beta gamma subunits of G proteins in targeting the beta-adrenergic receptor kinase to membrane-bound receptors. Science (1992) 3.45
Heart failure. Lancet (2005) 3.33
Physiological effects of inverse agonists in transgenic mice with myocardial overexpression of the beta 2-adrenoceptor. Nature (1995) 3.27
Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Lancet (1993) 3.20
Beta-arrestin-mediated beta1-adrenergic receptor transactivation of the EGFR confers cardioprotection. J Clin Invest (2007) 3.15
Linkage of beta1-adrenergic stimulation to apoptotic heart cell death through protein kinase A-independent activation of Ca2+/calmodulin kinase II. J Clin Invest (2003) 3.15
Progressive hypertrophy and heart failure in beta1-adrenergic receptor transgenic mice. Proc Natl Acad Sci U S A (1999) 3.13
Differential kinetic and spatial patterns of beta-arrestin and G protein-mediated ERK activation by the angiotensin II receptor. J Biol Chem (2004) 3.07
Requirement for Ca2+/calmodulin-dependent kinase II in the transition from pressure overload-induced cardiac hypertrophy to heart failure in mice. J Clin Invest (2009) 2.98
Expression of a beta-adrenergic receptor kinase 1 inhibitor prevents the development of myocardial failure in gene-targeted mice. Proc Natl Acad Sci U S A (1998) 2.76
Dual modulation of cell survival and cell death by beta(2)-adrenergic signaling in adult mouse cardiac myocytes. Proc Natl Acad Sci U S A (2001) 2.52
Epidemiology, pathophysiology, and etiology of congestive heart failure in older adults. J Am Geriatr Soc (1997) 2.46
Coupling of beta2-adrenoceptor to Gi proteins and its physiological relevance in murine cardiac myocytes. Circ Res (1999) 2.37
GPCR functional selectivity has therapeutic impact. Trends Pharmacol Sci (2007) 2.35
Ryanodine receptor phosphorylation by calcium/calmodulin-dependent protein kinase II promotes life-threatening ventricular arrhythmias in mice with heart failure. Circulation (2010) 2.32
Principles: receptor theory in pharmacology. Trends Pharmacol Sci (2004) 2.18
G-protein-coupled receptor kinase activity is increased in hypertension. J Clin Invest (1997) 2.16
Collateral efficacy in drug discovery: taking advantage of the good (allosteric) nature of 7TM receptors. Trends Pharmacol Sci (2007) 2.13
Akt mediates the cross-talk between beta-adrenergic and insulin receptors in neonatal cardiomyocytes. Circ Res (2004) 2.08
Cardiac beta ARK1 inhibition prolongs survival and augments beta blocker therapy in a mouse model of severe heart failure. Proc Natl Acad Sci U S A (2001) 1.97
Functional coupling of the beta 2-adrenoceptor to a pertussis toxin-sensitive G protein in cardiac myocytes. Mol Pharmacol (1995) 1.92
Activity of the sympathetic nervous system and renin-angiotensin system assessed by plasma hormone levels and their relation to hemodynamic abnormalities in congestive heart failure. Am J Cardiol (1982) 1.91
Carvedilol and its new analogs suppress arrhythmogenic store overload-induced Ca2+ release. Nat Med (2011) 1.88
Beta 1- and beta 2-adrenergic receptor-mediated adenylate cyclase stimulation in nonfailing and failing human ventricular myocardium. Mol Pharmacol (1989) 1.87
Increase of the 40,000-mol wt pertussis toxin substrate (G protein) in the failing human heart. J Clin Invest (1988) 1.85
Stereochemistry of an agonist determines coupling preference of beta2-adrenoceptor to different G proteins in cardiomyocytes. Mol Pharmacol (2008) 1.78
Comparative molecular field analysis of the binding of the stereoisomers of fenoterol and fenoterol derivatives to the beta2 adrenergic receptor. J Med Chem (2007) 1.77
Mechanism of beta-adrenergic receptor desensitization in cardiac hypertrophy is increased beta-adrenergic receptor kinase. J Biol Chem (1997) 1.71
Loss of beta-adrenoceptor response in myocytes overexpressing the Na+/Ca(2+)-exchanger. J Mol Cell Cardiol (2004) 1.68
Beta-blockers alprenolol and carvedilol stimulate beta-arrestin-mediated EGFR transactivation. Proc Natl Acad Sci U S A (2008) 1.67
Expression of beta-arrestins and beta-adrenergic receptor kinases in the failing human heart. Circ Res (1994) 1.66
Mechanisms of enhanced beta-adrenergic reserve from cardiac resynchronization therapy. Circulation (2009) 1.63
Activation of CaMKIIdeltaC is a common intermediate of diverse death stimuli-induced heart muscle cell apoptosis. J Biol Chem (2007) 1.61
Reciprocal in vivo regulation of myocardial G protein-coupled receptor kinase expression by beta-adrenergic receptor stimulation and blockade. Circulation (1998) 1.60
Preservation of myocardial beta-adrenergic receptor signaling delays the development of heart failure after myocardial infarction. Proc Natl Acad Sci U S A (2000) 1.57
Reduced beta 1 receptor messenger RNA abundance in the failing human heart. J Clin Invest (1993) 1.55
Enhanced G(i) signaling selectively negates beta2-adrenergic receptor (AR)--but not beta1-AR-mediated positive inotropic effect in myocytes from failing rat hearts. Circulation (2003) 1.55
Beneficial effects of chronic pharmacological manipulation of beta-adrenoreceptor subtype signaling in rodent dilated ischemic cardiomyopathy. Circulation (2004) 1.53
Beta 2-adrenergic receptor-stimulated increase in cAMP in rat heart cells is not coupled to changes in Ca2+ dynamics, contractility, or phospholamban phosphorylation. J Biol Chem (1994) 1.51
Myocardial-directed overexpression of the human beta(1)-adrenergic receptor in transgenic mice. J Mol Cell Cardiol (2000) 1.43
beta-Arrestin-dependent activation of Ca(2+)/calmodulin kinase II after beta(1)-adrenergic receptor stimulation. J Cell Biol (2010) 1.35
Reduction of sympathetic activity via adrenal-targeted GRK2 gene deletion attenuates heart failure progression and improves cardiac function after myocardial infarction. J Biol Chem (2010) 1.32
A beta1-adrenergic receptor CaM kinase II-dependent pathway mediates cardiac myocyte fetal gene induction. Am J Physiol Heart Circ Physiol (2006) 1.32
Pharmacological stimulation of beta2-adrenergic receptors (beta2AR) enhances therapeutic effectiveness of beta1AR blockade in rodent dilated ischemic cardiomyopathy. Heart Fail Rev (2005) 1.20
Cardioprotective and survival benefits of long-term combined therapy with beta2 adrenoreceptor (AR) agonist and beta1 AR blocker in dilated cardiomyopathy postmyocardial infarction. J Pharmacol Exp Ther (2008) 1.20
Increased nitration of sarcoplasmic reticulum Ca2+-ATPase in human heart failure. Circulation (2005) 1.19
Activation of beta-adrenergic receptor kinase during myocardial ischemia. Circ Res (1996) 1.15
The enigma of beta2-adrenergic receptor Gi signaling in the heart: the good, the bad, and the ugly. Circ Res (2005) 1.15
Restoration of beta-adrenergic receptor signaling and contractile function in heart failure by disruption of the betaARK1/phosphoinositide 3-kinase complex. Circulation (2005) 1.14
Level of beta-adrenergic receptor kinase 1 inhibition determines degree of cardiac dysfunction after chronic pressure overload-induced heart failure. Circulation (2005) 1.14
Enantioselective separation and online affinity chromatographic characterization of R,R- and S,S-fenoterol. Chirality (2006) 1.14
Progressive ventricular remodeling in response to diffuse isoproterenol-induced myocardial necrosis in rats. Circ Res (1994) 1.12
Comparative molecular field analysis of fenoterol derivatives: A platform towards highly selective and effective beta(2)-adrenergic receptor agonists. Bioorg Med Chem (2009) 1.09
Strain-dependent beta-adrenergic receptor function influences myocardial responses to isoproterenol stimulation in mice. Am J Physiol Heart Circ Physiol (2005) 1.08
Specific beta(2)AR blocker ICI 118,551 actively decreases contraction through a G(i)-coupled form of the beta(2)AR in myocytes from failing human heart. Circulation (2002) 1.07
Functional selectivity of GPCR ligand stereoisomers: new pharmacological opportunities. Mol Pharmacol (2008) 1.02
Gi-biased β2AR signaling links GRK2 upregulation to heart failure. Circ Res (2011) 1.01
β₂ AR agonists in treatment of chronic heart failure: long path to translation. J Mol Cell Cardiol (2010) 1.00
Phosphorylation of G protein-coupled receptors: GPCR kinases in heart disease. Mol Interv (2003) 0.99
Therapeutic efficacy of a combination of a beta1-adrenoreceptor (AR) blocker and beta2-AR agonist in a rat model of postmyocardial infarction dilated heart failure exceeds that of a beta1-AR blocker plus angiotensin-converting enzyme inhibitor. J Pharmacol Exp Ther (2009) 0.96
Beta-blockers in heart failure: are pharmacological differences clinically important? Heart Fail Rev (2004) 0.93
Effects of metoprolol on myocardial beta-adrenoceptors and Gi alpha-proteins in patients with congestive heart failure. Eur J Clin Pharmacol (1996) 0.91
Effect of angiotensin-converting enzyme inhibitors on ventricular remodeling and survival following myocardial infarction. Ann Pharmacother (1993) 0.90
Influence of isoproterenol and ouabain on excitation-contraction coupling, cross-bridge function, and energetics in failing human myocardium. Circulation (1996) 0.86
Na+/Ca2+ exchange linking beta2-adrenergic G(i) signaling to heart failure: associated defect of adrenergic contractile support. J Mol Cell Cardiol (2004) 0.86
Radioimmunochemical quantification of Gi alpha in right and left ventricles from patients with ischaemic and dilated cardiomyopathy and predominant left ventricular failure. J Mol Cell Cardiol (1994) 0.85
The renin-angiotensin system in left ventricular remodeling. Am J Cardiol (1996) 0.84
Beta-adrenoceptor stimulation potentiates insulin-stimulated PKB phosphorylation in rat cardiomyocytes via cAMP and PKA. Br J Pharmacol (2010) 0.83
Propranolol-induced bronchoconstriction: a non-specific side-effect of beta-adrenergic blocking therapy. Eur J Pharmacol (1981) 0.82
β2-Adrenergic receptor-induced transactivation of epidermal growth factor receptor and platelet-derived growth factor receptor via Src kinase promotes rat cardiomyocyte survival. Cell Biol Int (2012) 0.80
Vasospastic phenomena in patients treated with beta-adrenoceptor blocking agents. Acta Med Scand Suppl (1979) 0.76
Mechanisms of enhanced beta-adrenergic reserve from cardiac resynchronization therapy. Circulation (2009) 1.63
The N-glycoform of sRAGE is the key determinant for its therapeutic efficacy to attenuate injury-elicited arterial inflammation and neointimal growth. J Mol Med (Berl) (2013) 0.93
Design, generation, and testing of mammalian expression modules that tag membrane proteins. Protein Sci (2009) 0.90
Role of inositol 1,4,5-trisphosphate receptors in alpha1-adrenergic receptor-induced cardiomyocyte hypertrophy. Acta Pharmacol Sin (2006) 0.78
A new era for GPCR research: structures, biology and drug discovery. Acta Pharmacol Sin (2012) 0.78
[Genetic polymorphism of 16 Y-STR loci in Miao, Yao and Dong nationalities of Guangxi population]. Fa Yi Xue Za Zhi (2012) 0.75